

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

jc542 U.S. PTO
09/207188
12/08/98

Applicant(s) : MILAN S. BLAKE, ET AL.
Serial No. : 08/231,229 Group Art Unit: 1818
Filed : April 21, 1994 Examiner: P. Achutamurthy
For : GROUP A STREPTOCOCCUS POLYSACCHARIDE
IMMUNOGENIC COMPOSITIONS AND METHODS

BOX AF
Assistant Commissioner For Patents
Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. §1.132 OF MACLYN MCCARTY

I, Maclyn McCarty, declare:

1. I am ^{Vice-} President Emeritus of The Rockefeller University, New York, New York 10021. A copy of my Curriculum Vitae is attached as Exhibit 1.
2. I have read and understand the pending application as well as the Final Rejection in that application which was mailed on May 23, 1997. I have also read the publications cited by the Examiner in support of the grounds of rejection.
3. In the Final Rejection of May 23, 1997, I understand the Examiner to have rejected claims 3, 5-7, 9-12, 15, 16, 19-22, 24, 29-35, 37-43, 45-53 and 55-66 under 35 U.S.C. §102

and 103 because the Examiner contends that the cited publications disclose or teach Group A streptococcal polysaccharide and its use to confer protection against infections by Group A streptococcal bacteria.

4. In my view, this application discloses that the group A streptococcal carbohydrate has potential for development as a preventive vaccine for streptococcal infections. While the carbohydrate has been known and studied in many laboratories for eighty years, it had been considered without potential as an immunizing agent for most of that period. As the authors accurately describe in the introduction to the application, they first obtained evidence for antibodies providing protection against infection by various types of group A streptococci in experiments first published in 1995. This is the first evidence of which I am aware that antibodies to the carbohydrate had this potential.

5. The application is designed to allow the development of a practical vaccine for prevention of streptococcal disease in human populations.

6. The history of active research on streptococci goes back to the last century, but that dealing with the individual components of the microorganism and their role in causing disease began in the third decade of this century with the pioneering work of Rebecca C. Lancefield at the Rockefeller Institute for Medical Research (now Rockefeller University). She

discovered the type-specific antigens - called M protein - and their importance in streptococcal infection, and showed that ✓ anti-M antibodies protected against infection. Since there are several dozen different types of group A streptococci, each with its own M protein and each requiring a different anti-M antibody for immunity, streptococcal sore-throat was a notoriously recurring disease and school age children had repeated attacks, each with a different specific type of organism. With advancing age the incidence of infection decreases, suggesting some broader form of immunity that is not type-specific. It was this fact that led the applicants to reexamine the possible role of antibodies to the group A carbohydrate.

7. Dr. Lancefield also discovered the group carbohydrates, and used rabbit antibodies to this streptococcal ✓ component to divide streptococci into several serological groups, identifying group A as the one involved in most human infections. She found no evidence for a protective effect of antibodies to the carbohydrate. I was associated with Dr. Lancefield for ~~thirty-five years~~, as head of the Laboratory of Streptococcal Infections and associated clinical studies of Rheumatic Fever at Rockefeller. My studies on the group carbohydrate involved demonstrating that it was the major constituent of the bacterial cell wall and work on the composition and structure of the carbohydrate. This research was motivated by the possibility that the carbohydrate might conceivably be a factor in the

pathogenesis of rheumatic fever. I considered the issue of the possible role of anti-carbohydrate antibodies in protection against streptococcal infection to have been settled.

8. My view on this last point appeared in print as late as 1989. This was in a chapter on Streptococci that I wrote for the highly regarded textbook, *Microbiology* (B.D. Davis, R. Dulbecco, H.N. Eisen, & H.S. Ginsberg, Editors, 4th Edition, J.B. Lippincott, 1989). In this chapter (page 535) I began the section on Immunity with the following sentence: "Of the many varieties of antibodies that are generated in response to group A hemolytic streptococcal disease, only anti-M is known to protect ✓ the host against invasiveness of the organisms." None of the publications cited by the Examiner change my view that at the time the application was filed, those skilled in the art did not consider the Group A streptococcal polysaccharide to be relevant to conferring protective antibodies against infections by the Group A streptococcal bacteria.

9. There seems to be no question that the developments of the invention by applicants which relates to the activity of antibodies to group A polysaccharides are novel and worth pursuing for vaccine development.

10. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false

statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: November 24, 1997



Maclyn McCarty

CURRICULUM VITAE

Maclyn McCarty, M.D.

05/97

Jc542 U.S. PTO
09/207188



Born: June 9, 1911 - South Bend, Indiana

Education: Stanford University - A.B., 1933
Johns Hopkins University - M.D., 1937

1937-40 Intern and Assistant Resident in Pediatrics at the Johns Hopkins Hospital, Baltimore, Maryland.

1940-41 Fellow in Medicine at New York University School of Medicine in laboratory of Dr. William S. Tillett.

1941 to present At The Rockefeller Institute for Medical Research (now The Rockefeller University), New York, NY.

1941-42 Fellow in the Medical Sciences of the National Research Council with Dr. O.T. Avery.

1942-46 Active duty (USNR) with Naval Medical Research Unit at the Rockefeller Institute.

1946-48 Associate of the Rockefeller Institute and Associate Physician to the Hospital

1948-50 Associate Member and Associate Physician

1950-58 Member and Physician

1958-81 Professor

1960-74 Physician-in-Chief to the Hospital

1965-78 Vice President

1977-7/81 John D. Rockefeller, Jr. Professor

7/81 - Professor Emeritus

From 1946 to July 1981, head of laboratory concerned with biology of hemolytic streptococci and rheumatic fever.

1972-76 Adjunct Professor of Medicine, Cornell University Medical College.

Fields of Investigation:

Transformation of pneumococcal types and the genetic role of DNA; C-reactive protein; biology and immunochemistry of streptococci; nature of rheumatic fever.

Professional Societies:

American Academy of Arts and Sciences
American Association for the Advancement of Science
American Association of Immunologists
American Pediatric Society
American Philosophical Society
American Society for Microbiology
Association of American Physicians
Harvey Society (Life Member)
Interurban Clinical Club
National Academy of Sciences
New York Academy of Medicine
Sigma Xi
Peripatetic Club
Transplantation Society
Infectious Diseases Society of America

Honors:

Alpha Omega Alpha
Phi Beta Kappa
Eli Lilly Award in Bacteriology and Immunology - 1946
The Johns Hopkins Society of Scholars - 1975
D.Sc. (honoris causa) Columbia University - 1976
D.Sc. (Honoris causa) University of Florida - 1977
John D. Rockefeller, Jr. Professorship, The Rockefeller
University, 1977-81.
Waterford Biomedical Sciences Award of the Scripps Clinic and
Research Foundation - 1977
Deutsche Gesellschaft für Hygiene und Mikrobiologie (Honorary
Member) - 1978
Medal of the New York Academy of Medicine - 1979
American College of Physicians Award for achievement in medical
science - 1980
Robert Koch Gold Medal, Robert Koch Stiftung, West Germany - 1981
Order of the Republic, 1st degree, Egypt - 1982
D.Sc. (honoris causa) The Rockefeller University - 1982
Order of San Carlos, Republic of Columbia - 1984
Commander's Cross of the Order of Merit of the Federal Republic
of Germany -1984. (Der Deutsche Verdienst Kreuz)
D.Sc. (Hon.) - Medical College of Ohio - 1985
D.Sc. (Hon.) - Emory University - 1987
Jessie Stevenson Kovalenko Medal - Natl. Acad. Sci. - 1988
M.D. (Hon.) - University of Köln - 1988
D.Sc. (Hon.) - Wittenberg University (Ohio) - 1989
George M. Kober Medal - Assn. of Amer. Physicians - 1989
Wolf Prize in Medicine (Israel) - 1990
John Stearns Award for Lifetime Achievement in Medicine -
The New York Academy of Medicine - 1993
Albert Lasker Special Public Health Award - 1994
Doctor of Humane Letters (Hon.) - Mt. Sinai Sch. Med. - 1995

Professional Activities:

American Heart Association (1968-1972)
Member of Policy and Affiliate Relations Committee
Armed Forces Epidemiological Board
Associate Member Commission on Streptococcal and Staphylococcal Diseases (1948-1972)
Assembly of Life Sciences, National Research Council
Member of Executive Committee (1974-1977)
Associated Universities, Inc.
Trustee (1978-1981)
Brookhaven National Laboratory
Member of Visiting Committee to Medical Department - 1970s
Biomedical Research Center for Infectious Diseases, Cairo, Egypt
Member of Advisory Board (1978-1983)
The Harvey Society
Secretary (1947-1950); President 1971-72)
Health Research Council of the City of New York (dissolved 1975)
Member, Allergy and Infectious Disease Panel
Chairman of Council (1972-1975)
Helen Hay Whitney Foundation
Scientific Advisory Committee
Member, 1956-1996
Chairman, 1963-1996
Vice President, 1964-present
Member. Board of Trustees, 1964-present.
Institute of Medicine, National Academy of Sciences
Charter Member
Massachusetts General Hospital
Member Scientific Advisory Committee (1967-1969)
National Academy of Sciences
Chairman, Section of Medical Sciences (1971-1974)
Member of Council (1973-1976)
Member of Report Review Committee (1974-1978)
New York Heart Association
President (1969-1971)
Chairman, Advisory Council on Research (1971-1873)
Member of Executive Committee (1969-1979)
New York Community Trust
Member, Disribution Committee (1966-1974)
Public Health Research Institute of City of New York
Board of Directors, 1965?-present; Chairman (1984-1992)
Research Council, 1965?-1980?: Ckairman (1969-1977)
R.J.Reynolds Industries
Member, Advisory Committee for Biomedical Research (1978-1989)
Society for Experimental Biology and Medicine
President (1974-1975)
Stanford University School of Medicine
Member of Visiting Committee (1964-1972)
Scripps Clinic and Research Fouondation, La Jolla, CA
Member of Advisory Board (1980-1982)
Sterling-Winthrop Research Institute
Member, Research Board (1973-1976)

C.V. Whitney Laboratory of Exptl. Marine Biol. and Med. (U. Fla.)
Member, Board of Scientific Advisors, (1977-1983)
World Health Organization (1966-1971)
Member, Expert Advisory Panel on Chronic Degenerative Diseases

Editorial Activities:

Editor, The Journal of Experimental Medicine, 1963-present
Associate Editor, The Journal of Immunology, 1962-1970
Member, Editorial Board, Infection and Immunity, 1970-1981
Member, Editorial Board, Proceedings of the National Academy of
Sciences, 1972-1977

Current Interests:

Research:

The biology of group A streptococci and the pathogenesis of
rheumatic fever.

Organizational:

Board of Trustees, Helen Hay Whitney Foundation

Board of Directors, Public Health Research Institute

Editor, The Journal of Experimental Medicine

Current Addresses:

Home:	400 East 56th Street New York, NY 10022-4147	Tel.: (212) 371 2631 FAX : (212) 371 3162
Office:	The Rockefeller University 1230 York Avenue New York, NY 10021	Tel.: (212) 327 8158 FAX : (212) 327 8960

May 1997

BIBLIOGRAPHY

03/95

Maclyn McCarty, M.D.

1. The use of sulfapyridine in primary pneumococcic pneumonia and in pneumococcic pneumonia associated with measles (with H.L.Hodes, W.C.Stifler, Jr., E.Walker, and R.G.Shirley), *J. Pediat.*, 1939, 14, 417-446.
2. The effect of p-aminobenzoic acid on therapeutic and toxic action of sulfapyridine, *Proc. Soc. Exp. Biol. & Med.*, 1941, 46, 133-136.
3. The inactivating effect of sulfapyridine on the leukotoxic action of benzene (with W.S.Tillett), *J. Exp. Med.*, 1941, 74, 531-544.
4. The relation of a somatic factor to virulence of pneumococci (with C.M.MacLeod), *J. Clin. Invest.* (Abstract), 1942, 21, 647.
5. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III (with O.T.Avery and C.M.MacLeod), *J. Exp. Med.*, 1944, 79, 137-158.
6. Reversible inactivation of the substance inducing transformation of pneumococcal types, *J. Exp. Med.*, 1945, 81, 501-514.
7. Purification and properties of desoxyribonuclease isolated from beef pancreas, *J. Gen. Physiol.*, 1946, 29, 123-139.
8. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. II. Effect of desoxyribonuclease on the biological activity of the transforming substance (with O.T.Avery), *J. Exp. Med.*, 1946, 83, 89-96.
9. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. III. An improved method for the isolation of the transforming substance and its application to pneumococcus types II, III, and VI (with O.T.Avery), *J. Exp. Med.*, 1946, 83, 97-104.
10. Chemical nature and biological properties of the substance inducing transformation of pneumococcal types, *Bact. Rev.*, 1946, 10, 63-71.
11. Biochemical studies of the environmental factors essential in transformation of pneumococcal types (with H.E.Taylor and O.T.Avery), *Cold Spring Harbor Symposia Quant. Biol.*, 1946, 11, 177-183.
12. The occurrence during acute infections of a protein not normally present in the blood. IV. Crystallization of the C-reactive protein, *J. Exp. Med.*, 1947, 85, 491-498.
13. The modifying effects of certain substances of bacterial origin on the course of infection with pneumonia virus of mice (PVM) (with F.L.Horsfall, Jr.), *J. Exp. Med.*, 1947, 85, 623-646.

Express Mail Label No.:
EI086496261US

14. The antagonistic effect of certain substances of bacterial origin in the course of infection with pneumonia virus of mice (PVM) (with F.L.Horsfall, Jr.), *Transact. Assn. Amer. Phys.*, 1947, 60, 18-21.
15. Quantitative antistreptokinase studies in patients infected with group A hemolytic streptococci. A comparison with serum antistreptolysin and gamma globulin levels with special reference to the occurrence of rheumatic fever (with H.C.Anderson and H.G.Kunkel), *J. Clin. Invest.*, 1948, 27, 425-434.
16. The occurrence of nucleases in culture filtrates of group A hemolytic streptococci. *J. Exp. Med.*, 1948, 88, 181-188.
17. The inhibition of streptococcal desoxyribonucleases by rabbit and human antisera. *J. Exp. Med.*, 1949, 90, 543-553.
18. The determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever (with H.C.Anderson). *Amer. J. Med.*, 1950, 8, 445-455.
19. The occurrence in the rabbit of an acute phase protein analogous to human C-reactive protein (with H.C.Anderson). *J. Exp. Med.*, 1951, 93, 25-36.
20. The measurement of C-reactive protein in human sera. Comparison of the clinical tests on the basis of a quantitative method (with H.F.Wood). *J. Clin. Invest.*, 1951, 30, 616-622.
21. Present state of knowledge concerning pathogenesis and treatment of rheumatic fever. *Bull. N. Y. Acad. Med.*, 1952, 28, 307-320.
22. The biology of group A streptococci. In *Rheumatic Fever* (L.Thomas, Ed.) Univ. Minn. Press, 1952, pp. 61-71.
23. The immune response in rheumatic fever. In *Rheumatic Fever* (L.Thomas, Ed.) Univ. Minn. Press, 1952, pp. 136-149.
24. Present status of diagnostic tests for rheumatic fever. *Ann. Int. Med.*, 1952, 37, 1027-1034.
25. The lysis of group A hemolytic streptococci by extracellular enzymes of *Streptomyces albus*. I. Production and fractionation of the lytic enzymes. *J. Exp. Med.*, 1952, 96, 555-568.
26. The lysis of group A hemolytic streptococci by extracellular enzymes of *Streptomyces albus*. II. Nature of the cellular substrate attacked by the the lytic enzymes. *J. Exp. Med.*, 1952, 96, 569-580.
27. *Streptococcal Infections*. Editor. Columbia Univ. Press, 1954, 218pp.

28. The antibody response to streptococcal infections. In *Streptococcal Infections*, Chapter 10, pp.130-142.
29. Studies of diphtheria antitoxin in rheumatic fever subjects: Analysis of reactions to the Schick test and of antitoxin responses following hyper-immunization with diphtheria toxin (with W.J.Kuhns). *J. Clin. Invest.*, 1954, 33, 759-767.
30. The occurrence during acute infections of a protein not normally present in the blood. V. Physical-chemical properties of the C-reactive protein crystallized by a modified procedure (with H.F.Wood and R.J.Slater). *J. Exp. Med.*, 1954, 100, 71-79.
31. The lysis of group A streptococci by extracellular enzymes of *Streptomyces albus*. (Abstract) *Bull. N. Y. Acad. Med.*, 1954, 30, 993-994.
32. Hypersensitivity and inflammation. In *Transactions of the First National Conference on Research and Education in Rheumatic Disease* (J.J.Bunim, Ed.) Washington, 1954.
33. Laboratory aids in the diagnosis of rheumatic fever and in evaluation of disease activity (with H.F.Wood). *Amer. J. Med.*, 1954, 17, 768-774.
34. *Pasteurella multocida* septicemia in man (with A.G.Bearn & K.Jacobs). *Amer. J. Med.*, 1955, 18, 167-168.
35. *Streptococcus lactis* isolated from a patient with subacute bacterial endocarditis (with H.F.Wood & K.Jacobs). *Amer. J. Med.*, 1955, 18, 345-347.
36. Rheumatic Fever. In Cecil and Loeb *Textbook of Medicine*, 9th Edition, 1955, W.B.Saunders, Phila. p.167. 10th Edition 1959, p.148.
37. Variation in the group specific carbohydrate of group A streptococci. I. Immunochemical studies on the carbohydrates of variant strains (with R.C. Lancefield). *J. Exp. Med.*, 1955, 102, 11-28.
38. Meticorten in the treatment of rheumatic fever (with R.M.Krause, W.C.Robbins, & H.F.Wood). First International Conference on the Clinical and Metabolic Effects of Meticorten and Meticortelone, 1955, pp. 156-160.
39. Biologically active products of group A streptococci, In *Symposium on Rheumatic Fever*, New York Heart Association, 1956.
40. Prophylaxis of rheumatic fever, (New York Academy of Medicine Post-graduate Radio Program). *N.Y. State J. of Med.*, 1956, 56, 1670-1674.
41. Variation in the group specific carbohydrate of group A streptococci. II. Studies on the chemical basis for serological specificity of the carbohydrates. *J. Exp. Med.*, 1956, 104, 629-643.

42. The nature of rheumatic fever. *Circulation*, 1956, 14, 1138-1143.
43. The antistreptolysin O titer in rheumatic fever: Methods and Significance. *Bull. on Rheumatic Diseases*, VII (Supp.), Mar. 1957.
44. Arguments en faveur des rapports liant l'infection streptococcique au rhumatisme articulaire aigu. *Revue du Rhumatisme*, Spec. No., 1957.
45. Further studies on the chemical basis for the serological specificity of group A streptococcal carbohydrate. *J. Exp. Med.*, 1958, 108, 311-323.
46. The hemolytic streptococci. In *Bacterial and Mycotic Infections of Man*, (R.J.Dubos, Ed.), 3rd Edition, 1958, J.B.Lippincott, Phila., pp.248-276.
47. Cross-reactions of streptococcal A and V carbohydrates in type II anti-pneumococcal horse sera (with M.Heidelberger). *Proc. Nat. Acad. Sci.*, 1959, 45, 235-238.
48. The occurrence of polyglycerophosphate as an antigenic component of various Gram-positive bacterial species. *J. Exp. Med.*, 1959, 109, 361-378.
49. Studies on L forms and protoplasts of group A streptococci. I. Isolation, growth, and bacteriologic characteristics (with E.H.Freimer & R.M.Krause). *J. Exp. Med.*, 1959, 110, 853-874.
50. The C-reactive protein test. *Triangle*, 1960, 4, 142-147.
51. Chemical basis for the serological specificity of cell wall carbohydrates of group A streptococci. *Bull. Soc. Chim. Biol. (France)*, 1960, 42, 1661.
52. Studies on the chemical structure of the streptococcal cell wall. I. The identification of a mucopeptide in the cell walls of group A and A-variant streptococci (with R.M.Krause). *J. Exp. Med.*, 1961, 114, 127-140.
53. Multiplicity and specificity of group A streptococcal antigens. In *Immunochemical Approaches to Problems in Microbiology* (M.Heidelberger & O.J.Plescia, Eds.). Institute of Microbiology, Rutgers, 1961, pp.112-122.
54. Studies on the chemical structure of the streptococcal cell wall. II. The composition of group C cell walls and chemical basis for the serological specificity of the carbohydrate moiety with (R.M.Krause). *J. Exp. Med.*, 1962, 115, 49-62.
55. Variation in the group-specific carbohydrate of group C hemolytic streptococci (with R.M.Krause). *J. Exp. Med.*, 1962, 116, 131-140.
56. Agents of disease and genetically controlled variations in their virulence. In *Genetic Selection in Man* (W.J.Schull, Ed.), The Univ. of Michigan Press, Ann Arbor, 1963. (Third Macy Conference on Genetics, Princeton, NJ, Oct. 15-18, 1961).

57. The streptococcal cell wall and its biological significance. In *The Streptococcus, Rheumatic Fever, and Glomerulonephritis* (J. Uhr, Ed.). 1964, Williams & Wilkins Co., Baltimore, MD, pp. 3-18.
58. Missing links in the streptococcal chain leading to rheumatic fever. T. Duckett Jones Memorial Lecture. *Circulation*, 1964, 29, 488-493.
59. The role of D-alanine in the serological specificity of group A streptococcal glycerol teichoic acid. *Proc. Nat. Acad. Sci.*, 1964, 52, 259-265.
60. Cell wall antigens of Gram-positive bacteria (with S.J.Morse). *Advances in Immunol.*, 1964, 4, 249-286.
61. The hemolytic streptococci, In *Bacterial and Mycotic Infections in Man*, (R.J.Dubos & J.G.Hirsch, Eds.), 4th Edition, 1965, pp. 356-
62. Rheumatic fever (with E.H.Freimer), *Scientific American*, 1965, 213, 67-
63. The nature of the opaque colony variation in group A streptococci. *J. Hyg. (Cambridge)*, 1966, 64, 185-190.
64. Molecular biology and medicine. In *A Symposium on the Child* (J.A.Askin, R.E.Cooke, & J.A.Haller, Eds.). The Johns Hopkins Press, Balto, MD, 1967.
65. Intraphagocytic B-N-acetylglucosaminidase. Properties of the enzyme and its activity on group A streptococcal carbohydrate in comparison with soil bacillus enzyme (with E.A.Ayoub). *J. Exp. Med.*, 1968, 127, 833-851.
66. Electronmicroscopic studies on opaque colony variants of group A streptococci (with J. Swanson). *J. Bacteriol.*, 1969, 100, 505-511.
67. Summation of Symposium on Streptococci, Glomerulonephritis, and Renal Transplantation. *Transplantation Proceedings*, 1969, 1, 1032-1035.
68. The streptococcal cell wall. (Harvey Lecture, delivered 12/18/69). In *Harvey Lectures, Series 65*, Academic Press, NY, 1971, pp.73-96.
69. Theories of pathogenesis of streptococcal complications. In *Streptococci and Streptococcal Diseases, Recognition, Understanding, and Management*. (L.W.Wannamaker & J.M.Matsen, Eds.). Academic Press, NY, 1972.
70. Colin Munro MacLeod (1909-1972). Year Book of The American Philosophical Society, 1972, pp. 222-230.
71. Summation of Conference. In *Proceedings of Symposium on New Approaches for Inducing Natural Immunity to Pyogenic Organisms*. Dept. Health, Educ. & Welfare Publication No. 74-553 (NIH), 1975, pp. 165-170.
72. The Dalkon Shield controversy. Structural and bacteriological studies of IUD tails (with H.J.Tatum, F.H.Schmidt, D.Phillips, & W.M.O'Leary). *Jour.*

73. Multiple mouse protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens (with R.C.Lancefield & W.N.Everly). *J. Exp. Med.*, 1975, 142, 165-179.
74. Teichoic acids of group D streptococci with special reference to strains from pig meningitis (*Streptococcus suis*) (with S.D.Elliott & R.C.Lancefield). *J. Exp. Med.*, 1977, 145, 490-499.
75. Group A streptococcal antigens cross-reactive with myocardium (with I. van de Rijn & J.B.Zabriskie). *J. Exp. Med.*, 1977, 146, 579-599.
76. Summary of the Symposium: Current Status and Prospects for Improved and New Bacterial Vaccines. *J. Infect. Dis.*, 1977, 136, S253-S256.
77. The Streptococcus and Human Disease (Editorial). *Amer. J. Med.*, 1978, 65, 717.
78. The biology of group A streptococci. In *Symposium on Streptococcus, Rheumatic Fever, and Glomerulonephritis*, Mexico, D.F. 1978, Instituto Nacional de Cardiologia, pp.68-73.
79. Serial studies on circulating immune complexes in post-streptococcal sequelae (with I. van de Rijn, H. Fillit, W.E.Brandeis, H.Reid, T.Poon-King, N.K.Day, and J.B.Zabriskie). *Clin. & Exper. Immunol.*, 1978, 34, 318-325.
80. Amino acid sequence and structural similarities between streptococcal M protein and mammalian tropomyosin (with B.Hosein & V.A.Fischetti). *Proc. Nat. Acad. Sci.*, 1979, 76, 3765-3770.
81. Characterization and localization of the enzymatic deacylation of lipoteichoic acid in group A streptococci (with R.E.Kessler & I. van de Rijn). *J. Exp. Med.*, 1979, 150, 1498-1509.
82. The role of immunological mechanisms in the pathogenesis of rheumatic fever. In *Streptococcal Diseases and the Immune Response*, (S.E.Read & J.B.Zabriskie, Eds.). Academic Press, NY, 1980, pp.13-21.
83. An adventure in the pathogenetic maze of rheumatic fever. (The Maxwell Finland Lecture). *J. Infect. Dis.*, 1981, 143, 375-385.
84. Reminiscences of the early days of transformation. *Ann. Rev. Genetics*, 1980, 14, 1-15.
85. Nutritionally variant streptococci from patients with endocarditis: Growth parameters in a semisynthetic medium and demonstration of a chromophore (with A.Bouvet & I van de Rijn). *J. Bacteriol.*, 1981, 146, 1075-1082.

86. Release of lipoteichoic acid by group A streptococci (with R.E.Kessler & I. van de Rijn). In *Chemistry and Biological Activities of Bacterial Surface Amphiphils*. Academic Press, NY, 1981, pp.239-246.
87. Historical perspective on C-reactive protein. In *C-reactive Protein and the Plasma Protein Response to Tissue Injury* (I.Kushner, J.E.Volanakis, & H.Gewurz, Eds.) *Annals N.Y. Acad. Sci.*, 1982, 389, 1-10.
88. Immunochemical analysis of streptococcal group A, B, and C carbohydrates, with emphasis on group A (with J.C.Fung & K.Wicher). *Infect. & Immun.*, 1982, 37, 209-215.
89. On the unexpected fruits of mission-oriented research. *Proceedings of Amer. Philosoph. Soc.*, 1984, 128, 20-26.
90. *The Transforming Principle: Discovering that Genes Are Made of DNA*. 1985, W.W.Norton, NY. (252 pages).
91. Antibodies in bacterial and fungal infections. In *Antibodies: Protective, Destructive, and Regulatory Role* (9th International Convocation on Immunology, Buffalo, NY, 1984). F. Milgrom, Ed., 1985, Karger, Basel.
92. Lewis Wannamaker in the campaign against rheumatic fever. *Zentralblatt Bakt. Hyg. A*. 1985, 236, 151-164.
93. The induction of antibodies to hyaluronic acid by immunization of rabbits with encapsulated streptococci (with H.M.Fillit & M.Blake). *J. Exp. Med.*, 1986, 164, 762-776.
94. Modern biotechnology and world health. In *Modern Biotechnology and Health: Perspectives for the Year 2000* (M.E.Patarroyo, J.B.Zabriskie & D.Pizano-Salazar, Eds.). Academic Press, 1987, pp. 17-24.
95. Rebecca Craighill Lancefield, 1895-1981. *Biographical Memoirs*, Vol. 57, pp.227-246, The National Academy Press, 1987.
96. Stuart Dunsmore Elliott, 1907-1986. Obituary Notice. *J. Med. Microbiol.*, 1987, 23, 367-369.
97. Immunogenicity of liposome-bound hyaluronate in mice. At least two different antigenic sites on hyaluronate are identified by mouse monoclonal antibodies. (with H.M.Fillit, M.Blake, & C.MacDonald). *J. Exp. Med.*, 1988, 168, 971-982.
98. Acceptance of the George M. Kober Medal. *Transactions of the Assoc. of Amer. Physicians*, 1989, 102, cxi-cxlii.
99. Editorial. The Journal prepares for its second century. *J. Exp. Med.*, 1990, 172, 1-6.

100. Michael Heidelberger (29 April 1888 - 25 June 1991) *Proceedings of the Amer. Philosoph. Soc.*, 1993, 137, 433-437.
101. The early history of clinical investigation at the Rockefeller Institute. Occasional Papers of the Tri-Institutional Biomedical Forum. The Rockefeller University Hospital. 1993. (Delivered, 4 October 1992).
102. A retrospective look: How we identified the pneumococcal transforming substance as DNA. (From talk at 35th anniversary of 1944 paper.) *J. Exp. Med.*, 1994, 179, 381-394.
103. Colin Munro MacLeod. *Dictionary of American Biography. Supplement 9*, 1944.
104. A retrospective look at the discovery of the genetic role of DNA. *The FASEB Journal*, 1994, 8, 889-890.
105. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies (with L.G. Salvadori, M.S. Blake, J.Y.Tai, & J.B.Zabriskie). *J. Infect. Dis.*, 1995, 171, 593-600.